University of the Balearic Islands

Neuraxpharm appoints Alfredo Barón as Country Manager for Spain

Retrieved on: 
Thursday, June 2, 2022
Marketing, Molecular biology, Knowledge, MBA, Central nervous system, Corporation, CEO, Balearic Islands, University of the Balearic Islands, Cadmium telluride, GMP, Almirall, University, Growth, ESADE, Bachelor, CNS, Permira, McNeil Consumer Healthcare, Animal, Management, Pharmaceutical industry, IESE

BARCELONA, Spain and DUSSELDORF, Germany, June 2, 2022 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), has appointed Alfredo Barón as the new Country Manager of Neuraxpharm Spain, replacing Javier Mercadé who has been appointed Head of Growth Markets for developing markets such as Portugal, Greece, Switzerland, Ireland and the Nordic countries.

Key Points: 
  • As the new Country Manager of Neuraxpharm Spain, Barn will be responsible for continuing to expand the business in Spain and leading the launch of new, innovative product lines in the country.
  • Alfredo Barn has more than 20 years of experience in the pharmaceutical sector, both in Spain and internationally.
  • Dr Jrg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, stated: "We are extremely proud to announce the appointment of Alfredo Barn as the new Country Manager of Neuraxpharm Spain.
  • Alfredo Barn, Country Manager of Neuraxpharm Spain, expressed: "I am excited and grateful for the trust that Neuraxpharm has placed in me and to be part of this team.

Neuraxpharm appoints Alfredo Barón as Country Manager for Spain

Retrieved on: 
Thursday, June 2, 2022
Marketing, Molecular biology, Knowledge, MBA, Central nervous system, Corporation, CEO, Balearic Islands, University of the Balearic Islands, Cadmium telluride, GMP, Almirall, University, Growth, ESADE, Bachelor, CNS, Permira, McNeil Consumer Healthcare, Animal, Management, Pharmaceutical industry, IESE

BARCELONA, Spain and DUSSELDORF, Germany, June 2, 2022 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), has appointed Alfredo Barón as the new Country Manager of Neuraxpharm Spain, replacing Javier Mercadé who has been appointed Head of Growth Markets for developing markets such as Portugal, Greece, Switzerland, Ireland and the Nordic countries.

Key Points: 
  • As the new Country Manager of Neuraxpharm Spain, Barn will be responsible for continuing to expand the business in Spain and leading the launch of new, innovative product lines in the country.
  • Alfredo Barn has more than 20 years of experience in the pharmaceutical sector, both in Spain and internationally.
  • Dr Jrg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, stated: "We are extremely proud to announce the appointment of Alfredo Barn as the new Country Manager of Neuraxpharm Spain.
  • Alfredo Barn, Country Manager of Neuraxpharm Spain, expressed: "I am excited and grateful for the trust that Neuraxpharm has placed in me and to be part of this team.

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Retrieved on: 
Monday, November 22, 2021
Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, Population, FDI, University, Disease, Peripheral artery disease, Pain, Pharma, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, Balearic Islands, Wound healing, Vifor Pharma, Chronic kidney disease, Mortality, Dialysis, PAD, Cardiovascular disease, Fine chemical, Pharmaceutical industry

Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.

Key Points: 
  • Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the companys portfolio of innovative assets.
  • Todays exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group.
  • We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies.

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Retrieved on: 
Monday, November 22, 2021
Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, Population, FDI, University, Disease, Peripheral artery disease, Pain, Pharma, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, Balearic Islands, Wound healing, Vifor Pharma, Chronic kidney disease, Mortality, Dialysis, PAD, Cardiovascular disease, Fine chemical, Pharmaceutical industry

Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.

Key Points: 
  • Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the companys portfolio of innovative assets.
  • Todays exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group.
  • We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies.

Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, LR, Population, ART, FDI, University, Disease, Pain, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, CET, Balearic Islands, Wound healing, Foreign direct investment, CHF, Vifor Pharma, Lead, AVS, Chronic kidney disease, Mortality, Calcifying odontogenic cyst, Dialysis, PAD, Cardiovascular disease, CKD, Pharmaceutical industry, Vifor Pharma Group, SNF472, INS-3001, CUA, PAD, AVS, VIFOR PHARMA GROUP, SNF472, INS-3001, CUA, PAD, AVS

53 LR

Key Points: 
  • 53 LR
    Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.
  • Through these acquisitions, Vifor Pharma will be able to serve a continuum of vascular calcification disorders at all stages of CKD.
  • Acquisition of Sanifit is for the continued clinical development and commercialization of SNF472, a novel, first-in-class intravenously administered inhibitor of vascular calcification, for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Vifor Pharma will acquire 100% of the shares in Inositec AG, receiving full global rights for the lead asset INS-3001.